宿主靶向抗丙型肝炎病毒药物研究进展

李虎,蒋建东,彭宗根

中国药学杂志 ›› 2016, Vol. 51 ›› Issue (15) : 1265-1269.

PDF(685 KB)
PDF(685 KB)
中国药学杂志 ›› 2016, Vol. 51 ›› Issue (15) : 1265-1269. DOI: 10.11669/cpj.2016.15.001
综 述

宿主靶向抗丙型肝炎病毒药物研究进展

  • 李虎1,蒋建东1,2,彭宗根1*
作者信息 +

Research Progress of Anti-HCV Agents Targeting Host Factor

  • LI Hu1,JIANG Jian-dong1,2,PENG Zong-gen1*
Author information +
文章历史 +

摘要

近年来,抗丙型肝炎病毒(HCV)感染的治疗取得了很好的进展,特别是直接作用抗病毒药物(direct-acting antiviral agents, DAAs)的快速发展,使HCV感染的治愈提上日程,但DAAs的长期应用不可避免地会产生病毒耐药,导致治疗失败。为解决这一问题,宿主靶向药物 (host-targeting agents, HTAs) 的研发是重要策略之一。HTAs通过靶向作用于HCV生命周期各个阶段所必需的宿主因子,能有效减少病毒耐药并具有泛基因型抗病毒优势,与DAAs联合应用还具有协同抗病毒的效果并可降低药物毒副作用。笔者综述了现阶段临床前和临床在研的HTAs,为研发新型的抗HCV药物提供参考。

Abstract

Recently, the therapy of hepatitis C virus (HCV) infection, especially with the direct-acting antiviral agents (DAAs), has achieved many progresses. Although it is expected to cure HCV infection completely in the coming future, long-term application of DAAs will inevitably induce virus resistance, resulting in treatment failure. To solve this key problem, development of host-targeting agents (HTAs) emerges as one of effective strategies. HTAs targets the essential host factors for various stages of HCV life cycle, and thus has several advantages against HCV with reducing viral resistance, pan-genotypic antivirus, synergistic antiviral effects combined with known DAAs and decreasing side effects of drugs. This review summarized the recent progress of investigating HTAs in the pre-clinical and clinical study, to provide clues for the development of new anti-HCV drugs.

关键词

丙型肝炎病毒 / 宿主靶向药物 / 抗病毒 / 泛基因型

Key words

hepatitis C virus / host-targeting agent / viral resistance / pan-genotype

引用本文

导出引用
李虎,蒋建东,彭宗根. 宿主靶向抗丙型肝炎病毒药物研究进展[J]. 中国药学杂志, 2016, 51(15): 1265-1269 https://doi.org/10.11669/cpj.2016.15.001
LI Hu,JIANG Jian-dong,PENG Zong-gen. Research Progress of Anti-HCV Agents Targeting Host Factor[J]. Chinese Pharmaceutical Journal, 2016, 51(15): 1265-1269 https://doi.org/10.11669/cpj.2016.15.001
中图分类号: R969   

参考文献

[1] MOHD HANAFIAH K, GROEGER J, FLAXMAN A D, et al. Global epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence [J]. Hepatology, 2013, 57(4):1333-1342.
[2] MESSINA J P, HUMPHREYS I, FLAXMAN A, et al. Global distribution and prevalence of hepatitis C virus genotypes [J]. Hepatology, 2015, 61(1):77-87.
[3] ZOU J, CHEN H S H. Research progress of anti HCV drugs[J]. Chin Pharm J(中国药学杂志), 2004,39(6):403-408.
[4] FEENEY E R,CHUNG R T. Antiviral treatment of hepatitis C [J]. BMJ, 2014, 348:g3308.
[5] XU Y. New anti-HCV agent boceprevir [J]. Chin Pharm J(中国药学杂志), 2013,48(4):317-318.
[6] POORDAD F, MCCONE J J R, BACON B R, et al. Boceprevir for untreated chronic HCV genotype 1 infection [J]. N Engl J Med, 2011, 364(13):1195-1206.
[7] PAWLOTSKY J M. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus [J]. Hepatology, 2011, 53(5):1742-1751.
[8] BRIMACOMBE C L, GROVE J, MEREDITH L W, et al. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission [J]. J Virol, 2011, 85(1):596-605.
[9] BURLONE M E,BUDKOWSKA A. Hepatitis C virus cell entry:role of lipoproteins and cellular receptors [J]. J Gen Virol, 2009, 90(Pt 5):1055-1070.
[10] MORADPOUR D,PENIN F. Hepatitis C virus proteins:from structure to function [J]. Curr Top Microbiol Immunol, 2013, 369:113-142.
[11] LOHMANN V. Hepatitis C virus RNA replication [J]. Curr Top Microbiol Immunol, 2013, 369:167-198.
[12] LINDENBACH B D. Virion assembly and release [J]. Curr Top Microbiol Immunol, 2013, 369:199-218.
[13] DUBUISSON J,COSSET F L. Virology and cell biology of the hepatitis C virus life cycle--an update [J]. J Hepatol, 2014, 61(1 suppl):3-13.
[14] SULKOWSKI M S, KANG M, MATINING R, et al. Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults:a randomized, double-blind, phase 1b study [J]. J Infect Dis, 2014, 209(5):658-667.
[15] ZHU H, WONG-STAAL F, LEE H, et al. Evaluation of ITX5061, a scavenger receptor B1 antagonist:resistance selection and activity in combination with other hepatitis C virus antivirals [J]. J Infect Dis, 2012, 205(4):656-662.
[16] SAINZ B J R, BARRETTO N, MARTIN D N, et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor [J]. Nat Med, 2012, 18(2):281-285.
[17] LUPBERGER J, ZEISEL M B, XIAO F, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy [J]. Nat Med, 2011, 17(5):589-595.
[18] BARDOU-JACQUET E, LORHO R,GUYADER D. Kinase inhibitors in the treatment of chronic hepatitis C virus [J]. Gut, 2011, 60(6):879-880.
[19] PESTKA J M, ZEISEL M B, BLASER E, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C [J]. Proc Natl Acad Sci USA, 2007, 104(14):6025-6030.
[20] TIMPE J M, STAMATAKI Z, JENNINGS A, et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies [J]. Hepatology, 2008, 47(1):17-24.
[21] MEULEMAN P, CATANESE M T, VERHOYE L, et al. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo [J]. Hepatology, 2012, 55(2):364-372.
[22] MEULEMAN P, HESSELGESSER J, PAULSON M, et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo [J]. Hepatology, 2008, 48(6):1761-1768.
[23] FOFANA I, KRIEGER S E, GRUNERT F, et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes [J]. Gastroenterology, 2010, 139(3):953-964.
[24] FAFI-KREMER S, FOFANA I, SOULIER E, et al. Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation [J]. J Exp Med, 2010, 207(9):2019-2031.
[25] LAW M, MARUYAMA T, LEWIS J, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge [J]. Nat Med, 2008, 14(1):25-27.
[26] LI Y P, GOTTWEIN J M, SCHEEL T K, et al. MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5′UTR [J]. Proc Natl Acad Sci USA, 2011, 108(12):4991-4996.
[27] JANSSEN H L, REESINK H W, LAWITZ E J, et al. Treatment of HCV infection by targeting microRNA [J]. N Engl J Med, 2013, 368(18):1685-1694.
[28] BHAT B, NEBEN S, TAY J, et al. RG-101, a GalNAc-conjugated anti-miR employing a unique mechanism of action by targeting host factor microRNA-122(miR-122), demonstrates potent activity and reduction of HCV in preclinical studies [J]. Hepatology, 2013, 58(6):1393.
[29] LEE C H, KIM J H, KIM H W, et al. Hepatitis C virus replication-specific inhibition of microRNA activity with self-cleavable allosteric ribozyme [J]. Nucleic Acid Ther, 2012, 22(1):17-29.
[30] CHATTERJI U, BOBARDT M, SELVARAJAH S, et al. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication [J]. J Biol Chem, 2009, 284(25):16998-17005.
[31] TERAOKA S, MISHIRO S, EBIHARA K, et al. Effect of cyclosporine on proliferation of non-A, non-B hepatitis virus [J]. Transplant Proc, 1988, 20(3 suppl 3):868-876.
[32] OPKINS S, BOBARDT M, CHATTERJI U, et al. The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes [J]. Antimicrob Agents Chemother, 2012, 56(7):3888-3897.
[33] COELMONT L, HANOULLE X, CHATTERJI U, et al. DEB025(Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A [J]. PLoS One, 2010, 5(10):e13687.
[34] FLISIAK R, JAROSZEWICZ J, FLISIAK I, et al. Update on alisporivir in treatment of viral hepatitis C [J]. Expert Opin Investig Drugs, 2012, 21(3):375-382.
[35] FLISIAK R, HORBAN A, GALLAY P, et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus [J]. Hepatology, 2008, 47(3):817-826.
[36] OWENS C M, POLEMEROPOULOS A, LONG J, et al. Cyclophilin inhibitor EDP-546 is a potential cornerstone drug for use in combination with NS5A and protease inhibitors due to its high barrier to HCV resistance [J]. J Hepatol, 2013, 58:493.
[37] HOPKINS S, DIMASSIMO B, RUSNAK P, et al. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection [J]. J Hepatol, 2012, 57(1):47-54.
[38] KAPADIA S B,CHISARI F V. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids [J]. Proc Natl Acad Sci USA, 2005, 102(7):2561-2566.
[39] YE J, WANG C, SUMPTER R J R, et al. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation [J]. Proc Natl Acad Sci USA, 2003, 100(26):15865-15870.
[40] IKEDA M, ABE K, YAMADA M, et al. Different anti-HCV profiles of statins and their potential for combination therapy with interferon [J]. Hepatology, 2006, 44(1):117-125.
[41] RAO G A,PANDYA P K. Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C [J]. Gastroenterology, 2011, 140(1):144-152.
[42] BLANCHET M, SEIDAH N G,LABONTE P. SKI-1/S1P inhibition:a promising surrogate to statins to block hepatitis C virus replication [J]. Antiviral Res, 2012, 95(2):159-166.
[43] HUANG J T, TSENG C P, LIAO M H, et al. Hepatitis C virus replication is modulated by the interaction of nonstructural protein NS5B and fatty acid synthase [J]. J Virol, 2013, 87(9):4994-5004.
[44] EVANCHIK M, CAI H Y, FENG Q S, et al. TVB-2640, a novel anti-HCV agent, safely causes sustained host-target inhibition in vivo [J]. Hepatology, 2012, 56:1066-1067.
[45] YOSHIDA E, KUNIMOTO D, LEE S S, et al. Results of a phase II dose ranging study of orally administered celgosivir as monotherapy in chronic hepatitis C genotype-1 patients [J]. Gastroenterology, 2006, 130(suppl 2):784.
[46] DURANTEL D. Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection [J]. Curr Opin Investig Drugs, 2009, 10(8):860-870.
[47] KAITA K,YOSHIDA E,KUNIMOTO D,et al. Phase II proof of concept study of celgosivir in combination with peginterferon alfa-2b and ribavirin in chronic hepatitis C genotype-1 non-responder patients [J]. J Hepatol, 2007, 46:56-57.
[48] GASTAMINZA P, CHENG G, WIELAND S, et al. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion [J]. J Virol, 2008, 82(5):2120-2129.
[49] HUANG H, SUN F, OWEN D M, et al. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins [J]. Proc Natl Acad Sci USA, 2007, 104(14):5848-5853.
[50] POENISCH M, METZ P, BLANKENBURG H, et al. Identification of HNRNPK as regulator of hepatitis C virus particle production [J]. PLoS Pathog, 2015, 11(1):e1004573.
[51] GUO M, PEI R, YANG Q, et al. Phosphatidylserine-specific phospholipase A1 involved in hepatitis C virus assembly through NS2 complex formation [J]. J Virol, 2015, 89(4):2367-2377.
[52] PARENT R, QU X, PETIT M A, et al. The heat shock cognate protein 70 is associated with hepatitis C virus particles and modulates virus infectivity [J]. Hepatology, 2009, 49(6):1798-1809.
[53] PENG Z G, FAN B, DU N N, et al. Small molecular compounds that inhibit hepatitis C virus replication through destabilizing heat shock cognate 70 messenger RNA [J]. Hepatology, 2010, 52(3):845-853.
[54] CHEN D, CAI J, YIN J, et al. Lycorine-derived phenanthridine downregulators of host Hsc70 as potential hepatitis C virus inhibitors [J]. Future Med Chem, 2015, 7(5):561-570.
[55] CHOCKALINGAM K, SIMEON R L, RICE C M, et al. A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle [J]. Proc Natl Acad Sci USA, 2010, 107(8):3764-3769.
[56] GASTAMINZA P, WHITTEN-BAUER C,CHISARI F V. Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection [J]. Proc Natl Acad Sci USA, 2010, 107(1):291-296.

基金

国家自然科学基金委创新群体资助项目(81321004);国家自然科学基金委优秀青年科学基金资助项目(81322050);教育部新世纪优秀人才资助项目(NCET-12-0072)
PDF(685 KB)

Accesses

Citation

Detail

段落导航
相关文章

/